Original ArticleDistinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
Under an Elsevier user license
open archive
Key Words
EGFR
KRAS
Early-stage
Resected
Lung cancers
Non–small cell lung cancers
Adenocarcinomas
Cited by (0)
Disclosure: The authors declare no conflict of interest.
Copyright © 2012 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.